NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

LDK378 for previously treated anaplastic-lymphoma-kinase-positive non-small-cell lung cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Novartis Pharmaceuticals (LDK378) <u>Patient/carer groups</u> Afiya Trust Black Health Agency British Lung Foundation Cancer Black Care Cancer Equality Equalities National Council HAWC 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland
 Helen Rollason Cancer Charity Independent Cancer Patients Voice 	 Medicines and Healthcare products Regulatory Agency
 Macmillan Cancer Support Maggie's Centres Marie Curie Cancer Care 	 National Association of Primary Care National Pharmacy Association NHS Alliance
 Muslim Council of Britain Muslim Health Network 	NHS Commercial Medicines UnitNHS Confederation
Roy Castle Lung Cancer FoundationSouth Asian Health Foundation	Scottish Medicines Consortium
Specialised Healthcare Alliance	Possible comparator manufacturers
Tenovus	Accord Healthcare (docetaxel)
United Kingdom Lung Cancer	Actavis UK (docetaxel)
Coalition	Hospira UK (docetaxel)
Professional groups	Medac UK (docetaxel)Pfizer (crizotinib)
 Professional groups Association of Cancer Physicians 	 Sanofi (docetaxel)
,	 Teva UK (docetaxel)
 Association of Respiratory Nurse Specialists 	
British Geriatrics Society	Relevant research groups
British Institute of Radiology	British Thoracic Oncology Group
British Psychosocial Oncology Society	Cochrane Lung Cancer Group
British Thoracic Society	Health Research Authority
Cancer Network Pharmacists Forum	Institute of Cancer Research MPC Clinical Trials Unit
Cancer Research UK	MRC Clinical Trials Unit

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of LDK378 for previously treated anaplastic-lymphoma-kinase-positive non-small-cell lung cancer

Consultees	Commentators (no right to submit or appeal)
 National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers United Kingdom Clinical Pharmacy Association UK Health Forum United Kingdom Oncology Nursing Society Others Department of Health NHS England NHS Newbury and District CCG NHS Rotherham CCG Welsh Government 	 National Cancer Research Institute National Cancer Research Network National Institute for Health Research Research Institute for the Care of Older People Evidence Review Group Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups Public Health England Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Provisional matrix for the proposed technology appraisal of LDK378 for previously treated anaplastic-lymphoma-kinasepositive non-small-cell lung cancer

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Care Excellence